BioNexus Gene Lab Corp (BGLC) stock
BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3090% below fair value
$0.73−0.03 (-4.27%)
Close on Nov 18, 2026Market cap $2.15MP/E –Yield –
BioNexus Gene Lab net income
Net income is the profit left for shareholders after every expense, interest and tax.
BioNexus Gene Lab's net income for the twelve months ending Jun 30, 2026 was -$2.58M. For fiscal 2025 it was -$2.98M. The highest annual figure on record is $1.09M in fiscal 2020.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.98M | – |
| FY2024 | Dec 31, 2024 | -$1.60M | – |
| FY2023 | Dec 31, 2023 | -$2.63M | – |
| FY2022 | Dec 31, 2022 | -$355.97K | -147.4% |
| FY2021 | Dec 31, 2021 | $751.57K | -31.3% |
| FY2020 | Dec 31, 2020 | $1.09M | – |
| FY2019 | Dec 31, 2019 | -$246.47K | -1031.7% |
| FY2018 | Dec 31, 2018 | $26.45K | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$286.45K | – |
| Q1 FY2026 | Mar 31, 2026 | -$543.58K | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.04M | – |
| Q3 FY2025 | Sep 30, 2025 | -$708.99K | – |
| Q2 FY2025 | Jun 30, 2025 | -$616.17K | -409.5% |
| Q1 FY2025 | Mar 31, 2025 | -$623.33K | – |
| Q4 FY2024 | Dec 31, 2024 | -$348.32K | -212.9% |
| Q3 FY2024 | Sep 30, 2024 | -$1.35M | – |
| Q2 FY2024 | Jun 30, 2024 | $199.10K | – |
| Q1 FY2024 | Mar 31, 2024 | -$103.76K | – |
| Q4 FY2023 | Dec 31, 2023 | $308.46K | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.61M | – |
| Q2 FY2023 | Jun 30, 2023 | -$259.25K | – |
| Q1 FY2023 | Mar 31, 2023 | -$69.07K | -504.7% |
| Q4 FY2022 | Dec 31, 2022 | -$156.97K | -275.9% |
| Q3 FY2022 | Sep 30, 2022 | -$77.40K | -126.2% |
| Q2 FY2022 | Jun 30, 2022 | -$138.66K | -590.6% |
| Q1 FY2022 | Mar 31, 2022 | $17.07K | -95.0% |
| Q4 FY2021 | Dec 31, 2021 | $89.24K | – |
| Q3 FY2021 | Sep 30, 2021 | $295.32K | +26.0% |
| Q2 FY2021 | Jun 30, 2021 | $28.26K | – |
| Q1 FY2021 | Mar 31, 2021 | $338.74K | -68.3% |
| Q4 FY2020 | Dec 31, 2020 | -$174.16K | – |
| Q3 FY2020 | Sep 30, 2020 | $234.46K | – |
| Q2 FY2020 | Jun 30, 2020 | -$35.84K | – |
| Q1 FY2020 | Mar 31, 2020 | $1.07M | – |
| Q4 FY2019 | Dec 31, 2019 | -$92.58K | – |
| Q3 FY2019 | Sep 30, 2019 | -$22.03K | – |
| Q2 FY2019 | Jun 30, 2019 | -$70.40K | – |
| Q1 FY2019 | Mar 31, 2019 | -$61.47K | -122.6% |
| Q4 FY2018 | Dec 31, 2018 | -$62.97K | – |
| Q3 FY2018 | Sep 30, 2018 | -$88.96K | – |
| Q2 FY2018 | Jun 30, 2018 | -$39.47K | – |
| Q1 FY2018 | Mar 31, 2018 | $271.86K | – |
See a number that looks wrong?